Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia

DA Shah, RA Khalil - Biochemical pharmacology, 2015 - Elsevier
Preeclampsia is a pregnancy-associated disorder characterized by hypertension, and could
lead to maternal and fetal morbidity and mortality; however, the pathophysiological …

Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small‐for‐gestational‐age infants

AEP Heazell, DJL Hayes, M Whitworth… - Cochrane Database …, 2019 - cochranelibrary.com
Background Stillbirth affects 2.6 million pregnancies worldwide each year. Whilst the
majority of cases occur in low‐and middle‐income countries, stillbirth remains an important …

Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions …

SJ Korzeniewski, R Romero, T Chaiworapongsa… - American journal of …, 2016 - Elsevier
Background Placental lesions consistent with maternal vascular underperfusion (MVU) are
thought to be pathogenically linked to preeclampsia, small-for-gestational-age newborns …

Circulating biomarkers associated with placental dysfunction and their utility for predicting fetal growth restriction

J Hong, S Kumar - Clinical Science, 2023 - portlandpress.com
Fetal growth restriction (FGR) leading to low birth weight (LBW) is a major cause of neonatal
morbidity and mortality worldwide. Normal placental development involves a series of highly …

The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia

T Chaiworapongsa, R Romero, AE Whitten… - The Journal of …, 2016 - Taylor & Francis
Abstract Objective: To determine (1) whether maternal plasma concentrations of angiogenic
and anti-angiogenic factors can predict which mothers diagnosed with “suspected small for …

Systematic review of maternal Placental Growth Factor levels in late pregnancy as a predictor of adverse intrapartum and perinatal outcomes

H Sherrell, L Dunn, V Clifton, S Kumar - European Journal of Obstetrics & …, 2018 - Elsevier
Aim This systematic review evaluates the utility of maternal Placental Growth Factor (PlGF)
when measured in late pregnancy (> 20 weeks) as a predictor of adverse obstetric and …

Prediction of small‐for‐gestational‐age neonates: screening by biophysical and biochemical markers at 30–34 weeks

S Bakalis, G Peeva, R Gonzalez… - … in Obstetrics & …, 2015 - Wiley Online Library
Objective To investigate the potential value of combined screening by maternal
characteristics and medical history (maternal factors), estimated fetal weight (EFW), uterine …

[HTML][HTML] Prediction of preeclampsia and intrauterine growth restriction: development of machine learning models on a prospective cohort

H Sufriyana, YW Wu, ECY Su - JMIR medical informatics, 2020 - medinform.jmir.org
Background: Preeclampsia and intrauterine growth restriction are placental dysfunction–
related disorders (PDDs) that require a referral decision be made within a certain time …

Longitudinal changes in maternal serum placental growth factor and soluble fms‐like tyrosine kinase‐1 in women at increased risk of pre‐eclampsia

A Khalil, N Maiz, R Garcia‐Mandujano… - … in Obstetrics & …, 2016 - Wiley Online Library
Objectives To investigate longitudinal changes in maternal serum levels of placental growth
factor (PlGF) and soluble fms‐like tyrosine kinase‐1 (sFlt‐1) in pregnant women who …

Serum biomarkers combined with uterine artery Doppler in prediction of preeclampsia

L Li, Y Zheng, Y Zhu, J Li - … and therapeutic medicine, 2016 - spandidos-publications.com
First-trimester screening may be a major advantage over a second-trimester approach since
it opens prospects for early and more efficient interventions. The aim of the current study was …